Adverse dermatologic effects of cardiovascular drug therapy: Part III

Cardiology in Review

Volumn 10, Issue 6, 2002, Pages 337-348

  Frishman, William H ^a   Brosnan, Brian D ^a   Grossman, Marc ^a   Dasgupta, Debasish ^a   Sun, Diana K ^a  

^a NONE   (United States)

Author keywords

Adverse dermatologic effects; Anticoagulants antiplatelets antithrombotics; Cardiovascular disease; Lipid lowering drugs; Vasodilators

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARDEPARIN; CARDIOVASCULAR AGENT; CILOSTAZOL; CLONIDINE; DIAZOXIDE; DOXAZOSIN; FENOLDOPAM; GLYCERYL TRINITRATE; GUANABENZ; GUANETHIDINE; GUANFACINE; HYDRALAZINE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; ISOXSUPRINE; MECAMYLAMINE; METHYLDOPA; MINOXIDIL; PENTOXIFYLLINE; PRAZOSIN; PROSTACYCLIN; RESERPINE; SILDENAFIL; TERAZOSIN; TRIMETAPHAN; UNINDEXED DRUG; VASODILATOR AGENT;

ACNE; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; AGE; ALOPECIA; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; BULLOUS SKIN DISEASE; CARDIOVASCULAR DISEASE; CELLULITIS; DISEASE EXACERBATION; DRUG ERUPTION; DRY EYE; DRY SKIN; ECZEMA; ERYTHEMA; ERYTHEMA MULTIFORME; EXFOLIATIVE DERMATITIS; FACE EDEMA; FLUSHING; FURUNCULOSIS; GYNECOMASTIA; HERPES SIMPLEX VIRUS; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; LICHENOID ERUPTION; LIVEDO RETICULARIS; MUCOUS MEMBRANE PEMPHIGOID; PETECHIA; PHLEBITIS; PHOTOSENSITIVITY DISORDER; PITYRIASIS ROSEA; POPULATION RISK; PRURITUS; QUALITY OF LIFE; RASH; SKIN ALLERGY; SKIN BIOPSY; SKIN INFECTION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN NODULE; SKIN TOXICITY; SKIN ULCER; SWEATING; THROMBOCYTE ACTIVATION; URTICARIA; VASODILATATION; XEROSTOMIA;

EID: 0036842284     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045415-200211000-00006     Document Type: Article

References (133)

1. Physicians' Desk Reference, 53rd Ed. Medical Economics Co., Montvale, NJ, 1999.
2. Physicians' Desk Reference 50th Ed. Medical Economics Co., Montvale, NJ, 1996.
3. McEvov OK, ed: American Hospital Formulary Service Drug Information 1995. American Society of Hospital Pharmacists, Bethesda, MD, 1995.
4. Van Joost T, Faber WR, Manuel HR: Drug-induced anogenital cicatricial pemphigoid. Br J Dermatol 1980;102: 715-718.
5. Coulter DM, Pillans PI: Angiotensin-converting enzyme inhibitors and psoriasis. N Z Med J 1993;106:392-393.
6. Wilkin JK, Kirkendall WM: Pityriasis rosea-like rash from captopril. Arch Dermatol 1982;118:186-187.
7. Bork K: Cutaneous Side Effects of Drugs. WB Saunders Co., Philadelphia, 1988:3-18.
8. Witman G, Davis R: A lupus erythematosus syndrome induced by clonidine hydrochloride. R I Med 1981;164: 147-150.
9. Wilkin J: Exacerbation of psoriasis during clonidine therapy. Arch Dermatol 1981;117:4.
10. Wiser TH, Kazakis AM, LaCivita CL: Transdermal clonidine: An association with recurrent herpes simplex and hyperpigmentation. J Am Acad Dermatol 1987;17: 143-144.
11. Dick JBC, Northridge DB, Lawson AAH: Skin reactions to long-term transdermal clonidine. Lancet 1987;1:516.
12. Corazza M, Mantovani L, Virgili A, et al: Allergic contact dermatitis from a clonidine transdermal delivery system. Contact Dermatitis 1995;32:246.
13. McChesney JA: Preventing contact dermatitis caused by a transdermal clonidine patch. West J Med 1991;154:736.
14. Polster AM, Warner MR, Camisa C: Allergic contact dermatitis from transdermal clonidine in a patient with mycosis fungoides. Cutis 1999;63:154-155.
15. McMahon FG, Weber MA: Allergic skin reactions to transdermal clonidine. Lancet 1983;2:850-851.
16. Kuan P: Dangers of diazoxide. BMJ 1973;1:114.
17. GenRx: Physicians OnLine. 1996.
18. Lievre M, Azoulay S, Lion L, et al: A dose-effect study of beraprost sodium in intermittent claudication. J Cardiovasc Pharmacol 1996;27:788-793.
19. McEvoy GK, ed: American Hospital Formulary Service Drug Information 1998. American Society of Hospital Pharmacists, Bethesda, MD, 1998.
20. Mosby's GenRx. St. Louis, MO: Mosby, 2001.
21. Lee SL, Rivero I, Siegel M: Activation of systemic lupus erythematosus by drugs. Arch Intern Med 1966;117:620-626.
22. Hofstra AH: Metabolism of hydralazine: Relevance to drug-induced lupus. Drug Metab Rev 1994;26:485-505.
23. Yonga GD: Low dose hydralazine induced lupus. East Afr Med J 1992;9:649-650.
24. Davies DM, Ferner RE, de Glanville H: Davies's Textbook of Adverse Drug Reactions, Ed 5. Lippincott-Raven Publishers, New York, 1998.
25. Peterson II: Hydralazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum-like ulcers. J Am Acad Dermatol 1984;10:379-384.
26. Kiddin MW, Williamson RCN: Hydralazine-induced SLE-like syndrome presenting as a leg ulcer. BMJ 1979; 2:1330.
27. Petty R, Medley DRK: Cutaneous manifestations of hydralazine toxicity. BMJ 1980;280:482.
28. Sequeira W, Polinsky RB, Alrenga DP: Neutrophilic dermatosis (Sweet's syndrome). Am J Med 1986;81:558-560.
29. Servitje O, Ribera M, Juanola X, et al: Acute neutrophilic dermatosis associated with hydralazine induced lupus. Arch Dermatol 1987;123:1435-1436.
30. Almeyda J, Levantine A: Cutaneous reactions to cardiovascular drugs. Br J Dermatol 1973;88:313-319.
31. Thestrup-Pedersen K: Adverse reactions in the skin from antihypertensive drugs. Dan Med Bull 1987;34-5.
32. Korkij W, Soltani K: Fixed drug eruptions. Arch Dermatol 1984;120:520-524.
33. Wilkin JK: Vasodilator rosacea. Arch Dermatol 1980;116: 598.
34. Holt PJA, Navaratnam A: Lichenoid eruption due to methyldopa. BMJ 1974;3:234.
35. Vaillant L, Le Marchand D, Grognard C, et al: Photosensitivity to methyldopa. Arch Dermatol 1988;124:326-327.
36. Wells JD, Kurtay M, Lochner JC, et al: Granulomatous skin lesions and alpha-methyl dopa. Ann Intern Med 1974;81:701-702.
37. Mackie BS: Drug-induced ulcer of the lip. Br J Dermatol 1967;79:106-110.
38. Rausing A, Rosen U: Black cartilage after therapy with levodopa and methyldopa. Arch Pathol Lab Med 1994; 118:531-535.
39. Wolf R, Tamir A, Werbin N, et al: Methyldopa hypersensitivity syndrome. Ann Allergy 1993;71:166-168.
40. Burton JL, Marshall A: Hypertrichosis due to minoxidil. Br J Dermatol 1979;101:593-595.
41. DiSantis DJ, Flanagan J: Minoxidil-induced Stevens-Johnson syndrome. Arch Intern Med 1981;141:1515.
42. Ackerman BH, Townsend ME, Golden W, et al: Pruritic rash with actinic keratosis and impending exfoliation in a patient with hypertension managed with minoxidil. Drug Intell Clin Pharm 1988;22:702-703.
43. Kounis NG, Zavras GM, Papadaki PJ, et al: Allergic reactions to local glyceryl trinitrate administration. Br J Clin Pract 1996;50:437-439.
44. Fisher AA, Dec WD: Dermatitis due to transdermal therapeutic systems. Cutis 1984;34:526-531.
45. Torres V, Lopes JC, Leite L: Allergic contact dermatitis from nitroglycerin and estradiol transdermal therapeutic systems. Contact Dermatitis 1992;26:53-54.
46. de la Fuente Prieto R, Armentia Medina A, Diez Perez JM: Contact dermatitis from nitroglycerin. Ann Allergy 1994; 72:344-346.
47. Hendricks AA, Dec WD: Contact dermatitis due to nitroglycerine ointment. Arch Dermatol 1979;115:853-855.
48. Wutshert R, Piletta P, Bounameaux H: Adverse skin reactions to low molecular weight heparins: Frequency, management, and prevention. Drug Safety 1999;20:515-525.
49. Plath J, Schulze R, Barz D, et al: Necrotizing skin lesions induced by low-molecular-weight heparin after total knee arthroplasty. Arch Orthop Trauma Surg 1997;116: 443-445.
50. Cabanas R, Caballero MT, Lopez-Serrano MC, et al: Delayed hypersensitivity to enoxaparin. J Investig Allergol Clin Immunol 1998;8:383-384.
51. Gonzalo Garijo MA, Revenga Arranz F: Type IV hypersensitivity to subcutaneous heparin: A new case. J Investig Allergol Clin Immunol 1996;6:338-391.
52. Katz Y, Goldberg N, Kivity S: Localized periorbital edema induced by aspirin, Allergy 1993;45:366-369.
53. Baker H, Moore-Robinson M: Cutaneous responses to aspirin and its derivatives. Br J Dermatol 1970;82:319-321.
54. Brannen M, Forbes AF: Salicylate sensitivity. Tex J Med 1966;62:58-60.
55. Zhu DX, Zhao JL, Mo L, et al: Drug allergy: Identification and characterization of IgE-reactivities to aspirin and related compounds. J Investig Allergol Clin Immunol 1997;7:160-168.
56. Shelley WB: Birch pollen and aspirin psoriasis. JAMA 1964;189:985.
57. Sanchez-Borges M, Capriles-Hulett A: Atopy is a risk factor for non steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol 2000;84:101-106.
58. Santamaria A, Romani J, Souto JC, et al: Skin necrosis at the injection site induced by low-molecular weight heparin: Case report and review. Dermatology 1998;196:264-265.
59. Lefebvre I, Delaporte E, Dejobert Y, et al: Enoxaparin-induced cutaneous necrosis localized on insulin lipodystrophies. Ann Dermatol Venereol 1997;124:397-400.
60. Mendez J, Sanchis ME, de la Fuente R, et al: Delayed-type hypersensitivity to subcutaneous enoxaparin. Allergy 1998;53:999-1003.
61. Koch P, Hindi S, Landwehr D: Delayed allergic skin reactions due to subcutaneous heparin-calcium, enoxaparin-sodium, pentosan polysulfate and acute skin lesions from systemic sodium-heparin. Contact Dermatitis 1996;34:156-158.
62. Hirschboeck JS, Madison FW, Pisciotta AV: Alopecia and other toxic effects of heparin and synthetic heparinoids. Am J Med Sci 1965;227:279-282.
63. Chernoff AI: Anaphylactic reaction following injection of heparin. N Engl J Med 1950;242:315-319.
64. Oden M, Oliven A: Urticaria and angioedema induced by low-molecular-weight heparin. Lancet 1992;340:972-973.
65. Warkentin TE: Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998;35:9-16.
66. Chong BH: Heparin-induced thrombocytopenia. Aust N Z J Med 1992;22:145-152.
67. Warkentin TE, Levine MN, Hirsh J, et al: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;32:1330-1335.
68. Aster RH: Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;332:1374-1376.
69. Angus B, Abadir AR, Chaudry MR, et al: Heparin-induced thrombocytopenia. Proc West Pharmacol Soc 1994;37:101-102.
70. Warkentin TE, Kelton JG: Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991;10:1-34.
71. Gross AS, Thompson FL, Arzubiaga MC, et al: Heparin-associated thrombocytopenia and thrombosis presenting with livedo reticularis. Int J Dermatol 1993;32:276-279.
72. Boon DM, Michiels JJ, Stippe J, et al: Heparin-induced thrombocytopenia and antithrombotic therapy. Lancet 1994;344:1296.
73. Phillips DE, Payne DK, Milis GM: Heparin-induced thrombotic thrombocytopenia. Ann Phamacother 1994; 28:43-46.
74. Demasi R, Bode AP, Knupp C, et al: Heparin-induced thrombocytopenia. Am Surg 1994;60:26-29.
75. Rama BN, Haake RE, Bander SJ, et al: Heparin-flush associated thrombocytopenia-induced hemorrhage: A case report. Nebr Med J 1991;76:392-394.
76. Gruel Y, Rupin A, Watier H, et al: Anticardiolipin antibodies in heparin associated thrombocytopenia. Thromb Res 1992;67:601-606.
77. Kelly RA, Gelfand JA, Pincus SH: Cutaneous necrosis caused by systemically administered heparin. JAMA 1981;246:1582-1583.
78. Gold JA, Watters AK, O'Brien E: Coumadin versus heparin necrosis. J Am Acad Dermatol 1987;16:148-149.
79. Levine LE, Bernstein JE, Soltani K, et al: Heparin induced necrosis unrelated to injection sites: A sign of potentially lethal complications. Arch Dermatol 1983;119:400-403.
80. Leblanc M, Roy LF, Legault L, et al: Severe skin necrosis associated with heparin in hemodialysis. Nephron 1994; 68:133-137.
81. Real E, Grau E, Rubia M, et al: Skin necrosis after subcutaneous low molecular weight heparin injection. Am J Hematol 1995;49:253-254.
82. Ojeda E, Perez MC, Mataix R, et al: Skin necrosis with a low molecular weight heparin. Br J Haematol 1992;82:620.
83. Jumphries JE, Kaplan DM, Bolton WK: Heparin skin necrosis: Delayed occurrence in a patient on hemodialysis. Am J Kidney Dis 1991;17:233-236.
84. Yates P, Jones S: Heparin skin necrosis: An important indicator of potentially fatal heparin hypersensitivity. Clin Exp Dermatol 1993;18:138-141.
85. Harenberg J, Huhle G, Wang L, et al: Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG. Allergy 1999;54:473-477.
86. O'Toole RD: Heparin: Adverse reaction. Ann Intern Med 1973;79:759.
87. Koch P, Bahmer FA, Schafer A: Tolerance of intravenous low-molecular-weight heparin after eczematous reaction to subcutaneous heparin. Contact Dermatitis 1991;25: 205-206.
88. Valsecchi R, Rozzoni M, Cainelli T: Allergy to subcutaneous heparin. Contact Dermatitis 1992;26:129-130.
89. Mathelier-Fusade P, Deschamps A, Abuaf N, et al: Skin reactions to heparin: immunologic and clinical features. Presse Med 1995;24:323-325.
90. Mohammed KN: Symmetric fixed eruption to heparin. Dermatology 1995;190:91.
91. Bircher AJ, Itin PH, Buchner SA: Skin lesions, hypereosinophilia, and subcutaneous heparin. Lancet 1994;343: 861.
92. Giustolisi R, Guglielmo P, di Raimondo F, et al: Hypereosinophilia and subcutaneous heparin. Lancet 1993;342:1371.
93. Fox JG, Waili RK, Jaffray B, et al: Calcified subcutaneous nodules due to calcium heparin injections in a patient with chronic renal failure. Nephrol Dial Transplant 1994; 9:187-188.
94. Roche Pharmaceuticals. Ticlid (ticlopidine) package insert. Nutley, NJ, 1998.
95. Yosipovitch G, Rechavia E, Feinmesser M, et al: Adverse cutaneous reactions to ticlopidine in patients with coronary stents. J Am Acad Dermatol 1999;41:473-476.
96. Whetsel TR, Bell DM: Rash in patients receiving ticlopidine after intracoronary stent placement. Pharmacotherapy 1999;19:288-231.
97. Nalbandian RM, Mader IJ, Barret JL: Petechiae, ecchymoses, and necrosis of skin induced by Coumadin congeners. JAMA 1965;192:107-112.
98. Verhagen H: Local hemorrhage and necrosis of the skin and underlying tissues during anticoagulant therapy with dicumarol and dicumarcyl. Acta Med Scand 1954;148: 453-462.
99. Flood EP, Redish MH, Bociek SJ: Thrombophlebitis migrans disseminate: Report of a case in which gangrene of the breast occurred. N Y State J Med 1943;43:1121-1124.
100. Sternberg MC, Pettyjohn FS: Warfarin sodium-induced skin necrosis. Ann Emerg Med 1995;26:94-97.
101. Cole MS, Minifee PK, Wolma FJ: Coumarin necrosis: A review of the literature. Surgery 1988;103:271-276.
102. Kwong P, Roberts P, Prescott SM: Dermatitis induced by warfarin. JAMA 1978;239:1884-1885.
103. Hermes B, Haas N, Henz BM: Immunopathological events of adverse cutaneous reactions to coumarin and heparin. Acta Derm Venereol 1997;77:35-38.
104. Eby CS: Warfarin-induced skin necrosis. Hematol Oncol Clin North Am 1993;7:1291-1300.
105. Anderson DR, Brill-Edwards P, Walker I: Warfarin-induced skin necrosis in two patients with protein S deficiency: Successful reinstatement of warfarin therapy. Hemostasis 1992;22:124-128.
106. Defranzo AJ, Marasco P, Argenta LC: Warfarin-induced necrosis of the skin. Ann Plast Surg 1995;34:203-208.
107. Adams CW, Pass BJ: Extensive dermatitis due to warfarin sodium. Circulation 1960;22:947-948.
108. Schiff BL, Kern AB: Cutaneous reactions to anticoagulants. Arch Dermatol 1968;98:136-137.
109. Antony SJ, Krick SK, Menta PM: Unusual cutaneous adverse reaction to warfarin therapy. South Med J 1993; 86:1413-1414.
110. Sheps SG, Gifford RW: Urticaria after administration of warfarin sodium. Am J Cardiol 1959;3:118-120.
111. Feder W, Auerbach R: "Purple Toes": An uncommon sequelae of oral coumarin drug therapy. Ann Intern Med 1961;55:911-917.
112. Soisson AP, Vu KK, Brittain PC, et al: An unusual cutaneous reaction to anticoagulant therapy. Milit Med 1994; 159:252-253.
113. Park S, Schroeter AL, Park YS, et al: Purple toes and livedo reticularis in a patient with cardiovascular disease taking Coumadin: Cholesterol emboli associated with Coumadin therapy. Arch Dermatol 1993;129:777-780.
114. Baker H, Levene GM: Cutaneous reactions to anticoagulants. Br J Dermatol 1969;81:236-238.
115. Khanlou H, Malhotra G, Khanlou N, et al: Massive subfascial hematoma after alteplase therapy for acute myocardial infarction. Am J Med Sci 1999;317:53-54.
116. Arora RR, Magun AM, Grossman ME, et al: Cholesterol embolization syndrome after intravenous tissue plasminogen activator for acute myocardial infarction. Am Heart J 1993;126:225.
117. Adorati M, Pizzolitto S, Franzon R, et al: Cholesterol embolism and acute interstitial nephritis: Two adverse effects of streptokinase thrombolytic therapy in the same patient. Nephrol Dial Transplant 1998;13:1262-1264.
118. Geraets DR, Hoehns JD, Burke TG, et al: Thrombolytic-associated cholesterol emboli syndrome: Case report and literature review. Pharmacotherapy 1995;15:441-450.
119. Selvaag E: Clinical drug photosensitivity: A retrospective analysis of reports to the Norwegian adverse drug reactions committee from the years 1970-1994. Photodermatol Photoimmunol Photomed 1997;13:21-23.
120. Konig C, Eickert A, Scharfetter-Kochanek K, et al: Linear IgA bullous dermatosis induced by atorvastatin. J Am Acad Dermatol 2001;44:689-692.
121. Wolverton SE: Update on cutaneous drug reactions. Adv Dermatol 1998;13:65-84.
122. Krasovec M, Elsner P, Burg G: Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology 1993;186:248-252.
123. Wong SS: Stevens-Johnson syndrome induced by clofibrate. Acta Derm Venereol 1994;74:475.
124. Yamada S, Yagi A, Shiraishi S, et al: A case of extensive subcutaneous sarcoidosis. J Dermatol 1986;13:217.
125. Marguery MC, Chouini-Lalanne N, Ader JC, et al: Comparison of the DNA damage photoinduced by fenofibrate and ketoprofen, two phototoxic drugs of parent structure. Photochem Photobiol 1998;68:679-684.
126. Marguery MC, Sayed FE, Rakotondrazafy J, et al: Photoallergy and photoaggravation induced by fenofibrate: Cross photoreaction and transient light reaction. Eur J Dermatol 1995;5:204-207.
127. Smith GW, Hurst NP: Vasculitis, Raynaud's phenomenon, and polyarthritis associated with gemfibrozil therapy. Br J Rheum 1993;32:84-85.
128. Ahmed S: Lovastatin-induced lupus erythematosus. Arch Intern Med 1991;151:1667-1668.
129. Jungnickel PW, Maloley PA, Vander Tuin EL, et al: Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997;12:591-596.
130. Stals H, Vercammen C, Peeters C, et al: Acanthosis nigricans caused by nicotinic acid: Case report and review of the literature. Dermatology 1994;189:203-206.
131. Charman RC, Matthews LB, Braculer C: Nicotinic acid in the treatment of hypercholesterolemia. Angiology 1972; 23:29-35.
132. Mehregan DR, Mehregan DA, Pakideh S: Cheilitis due to treatment with simvastatin. Cutis 1998;62:197-198.
133. Morimoto K, Kawada A, Kiruma M: Photosensitivity to simvastatin with an unusual response to photopatch and photo tests. Contact Dermatitis 1995;33:274.